Maryland Clinical Trials

A listing of Maryland clinical trials actively recruiting patient volunteers.

Filter by Condition
2796 trials found

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough


Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC). Study drug BAY1817080 is a new drug under development for the treatment of long-standing cough. It blocks proteins that are expressed by the airway sensory nerves which are oversensitive in patients with long-standing cough. This prevents the urge to cough. Researchers also want to learn the ...

Conditions: Refractory and/or Unexplained Chronic Cough

A Comparison of Computer Vision Based Approach vs. Dual Energy X-ray Absorptiometry Scan to Measure Body Fat Percentage


This study is being done to test whether a HealthReel computer vision-based software application can estimate body fat percentage with equivalent accuracy to a whole body dual energy x-ray absorptiometry scan.

Conditions: Health Behavior

Remote Guided Caffeine Reduction


The purpose of this online research study is to determine whether or not a gradual caffeine reduction program developed at Johns Hopkins can help people reduce the caffeine use. The investigators will provide materials to help guide caffeine reduction and ask questions to track caffeine use over several weeks. The investigators will also assess how reducing caffeine may benefit common caffeine-related problems such as anxiety, sleep disturbances, and gastrointestinal distress. The study will als ...

Conditions: Caffeine Dependence, Anxiety, Sleep Disturbance, Gastrointestinal Dysfunction, Sleep Initiation and Maintenance Disorders, Caffeine; Sleep Disorder, Caffeine, Caffeine-Induced Anxiety Disorder, Caffeine Withdrawal, Caffeine-Induced Sleep Disorder, Without Use Disorder, Caffeine Abuse, Insomnia, Anxiety Disorders, Sleep Disorder, Heartburn, Diarrhea
Phase: Not Applicable

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes


This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for ...

Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency


The purpose of this study is to demonstrate bioequivalence of IVIG-PEG with Gamunex-C at steady-state as determined by comparing total Immunoglobulin G (IgG) area under the concentration-time curve during the defined dosing interval ([AUC0-τ] either every 3 weeks [AUC0-21 days] or every 4 weeks [AUC0-28 days]) and maximum concentration in a dosing interval (Cmax) in participants diagnosed with primary humoral immunodeficiency (PI) currently receiving chronic IVIG replacement treatment.

Conditions: Primary Immunodeficiency

A Natural History Study to Evaluate Functional and Anatomical Progression in Retinitis Pigmentosa


This study will assess the progression of RP as seen on newer modalities including spectral-domain optical coherence (SD-OCT) and macular assessment integrity (MAIA) microperimetry to evaluate disease status. Understanding the natural history of the disease is not only essential to monitoring and comparing patient populations in clinical trials. It is also fundamental in the predevelopment phase in order to optimize the study duration needed to observe a statistically significant outcome. Furthe ...

Conditions: Retinitis Pigmentosa

imPulse™ Una Full-spectrum, Over Clothing E-stethoscope


This study generates robust clinical data to train ML/AI algorithms of the Sponsor's imPulse™ Una full-spectrum e-stethoscope for digital diagnostic feature synthesis of symptomatic SARS-CoV-2/COVID-19 biosignatures for rapid and accurate mass screening.

Conditions: Corona Virus Infection, Coronavirus

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test


Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.

Conditions: Covid19
Phase: Not Applicable

RECORD-VP: Real-time Evaluation of Cardiac Outpatient Recording Device With VitalPatch RTM


The primary purpose of this study is to evaluate performance and safety of the VitalConnect Platform when used for mobile cardiac telemetry (MCT) or as an independent diagnostic testing facility (IDTF) system during activities of daily living by subjects 18 years or older who have been recommended MCT by their care provider.

Conditions: Arrhythmias, Cardiac

Natural Versus Programmed Frozen Embryo Transfer (NatPro)


NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing FET will be randomized to receive either a modified natural cycle (corpus luteum present) or a programmed cycle (corpus luteum absent).

Conditions: Pregnancy Related, Pre-Eclampsia

Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study


The purpose of this study is to compare the Vivaer procedure with radiofrequency (RF) energy to sham procedure for treatment of nasal airway obstruction (NAO).

Conditions: Nasal Airway Obstruction
Phase: Not Applicable

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)


This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks in participants with PPMS, in comparison to the approved 600 mg dose of ocrelizumab.

Conditions: Multiple Sclerosis